Elpiscience, Astellas collaborate on novel bispecific macrophage engagers
Elpiscience will receive up to $37m in upfront payment and license option fees, research funding from Astellas, and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Dec 23
Elpiscience will receive up to $37m in upfront payment and license option fees, research funding from Astellas, and…
27 Dec 23
The acquisition adds RayzeBio’s differentiated actinium-based radiopharmaceutical platform, including a pipeline of multiple drug development programmes to BMS’s…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 23
The ligand-conjugated antisense oligonucleotide, which is specifically designed to decrease the production of the transthyretin protein, was approved…
22 Dec 23
The collaboration combines Oncoshot's proficiency in data analysis and insights generation with Ablaze's recent expansion into data management…
22 Dec 23
Both firms will use EVQLV's proprietary artificial intelligence-powered Antibody Design Engine to generate novel antibodies against multiple targets…
22 Dec 23
Through the new collaboration, ImmunoScape and EDDC will jointly develop novel off-the-shelf TCR-based bispecific molecules using ImmunoScape’s database…
22 Dec 23
The programme aims to design a potential best in class molecule by combining Exscientia's research platform with Sanofi's…
22 Dec 23
Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus (Synergy) will be stopped to allow…
21 Dec 23
The regular approval from the US regulator pertains to the use of the B-cell immunomodulator to mitigate the…
21 Dec 23
Under the agreement, GSK will gain exclusive worldwide rights to progress the clinical development and commercialisation of the…